You are in: eMedicine Specialties > Pediatrics: General Medicine > Gastroenterology EncopresisArticle Last Updated: Mar 24, 2008AUTHOR AND EDITOR INFORMATIONAuthor: Stephen Borowitz, MD, Professor of Pediatrics and Public Health Sciences, Department of Pediatrics, Division of Gastroenterology and Nutrition, University of Virginia Stephen Borowitz is a member of the following medical societies: American Academy of Pediatrics, American Gastroenterological Association, American Pediatric Society, North American Society for Pediatric Gastroenterology and Nutrition, and Society for Pediatric Research Editors: Jorge H Vargas, MD, Clinical Professor of Pediatrics, Division of Pediatric Gastroenterology, Hepatology & Nutrition; Mary L Windle, PharmD, Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy, Pharmacy Editor, eMedicine.com, Inc; Steven M Schwarz, MD, FAAP, FACN, AGAF, Professor of Pediatrics, State University of New York, Downstate Medical Center College of Medicine; Distinguished Lecturer, New York Medical College, School of Public Health; Carmen Cuffari, MD, Associate Professor, Department of Pediatrics, Division of Gastroenterology/Nutrition, Johns Hopkins University School of Medicine Author and Editor Disclosure Synonyms and related keywords: encopresis, fecal incontinence, soiling, fecal soiling, retentive encopresis, nonretentive encopresis, feces, stool, rectal distention, overflow diarrhea, overflow, chronic diarrhea, constipation, painful bowel movements, soiling episodes, megacolon INTRODUCTIONBackgroundAccording to the Diagnostic and Statistical Manual of Mental Disorders, Third edition (DSM-III), encopresis is defined as the "repeated involuntary passage of feces into places not appropriate for that purpose...the event must take place for at least 6 months, the chronologic and mental age of the child must be at least 4 years."1 PathophysiologyIn the vast majority of cases, encopresis develops as a consequence of chronic constipation with resulting overflow incontinence,2 which is typically termed retentive encopresis. Chronic constipation due to irregular and incomplete evacuation results in progressive rectal distention and stretching of both the internal anal sphincter and the external anal sphincter (EAS). As the child habituates to chronic rectal distention, he or she no longer senses the normal urge to defecate. Soft or liquid stool eventually leaks around the retained fecal mass, resulting in fecal soiling. Approximately 80-95% of children with encopresis have a history of constipation or painful bowel movements. The remaining 5-20% are said to have nonretentive encopresis; however, many of these children have a remote history of constipation or painful defecation3 or demonstrate incomplete evacuation during defecation upon physical examination or radiographic assessment.4 Little or no evidence indicates that encopresis is primarily a behavioral disorder, and most available evidence suggests that behavioral difficulties associated with encopresis may be the result of the encopresis and not the cause.5 Low self-esteem or parent-child conflict as a result of the disorder is not uncommon. Embarrassed youngsters also commonly deny having the problem. FrequencyUnited StatesAlthough few prospective studies have been conducted to examine the prevalence of encopresis in childhood, an estimated 1-2% of children younger than 10 years have encopresis. In one study, 4.4% of 482 children aged 4-17 years observed over a 6 month period in a primary care pediatric clinic in Iowa experienced fecal incontinence at least once per week.6 InternationalAlthough population-based studies that examine the prevalence of encopresis are scarce, nearly all published studies have been conducted in North America and Europe. In one population-based study conducted in the Netherlands, 4.1% of children aged 5-6 years and 1.6% of children aged 11-12 years experienced fecal soiling at least once a month.7 Studies conducted in Sweden and the United Kingdom8 have reported similar numbers. SexIn nearly all published series, boys are much more commonly affected than girls. In most series, approximately 80% of affected children are boys. CLINICALHistoryApproximately 80-95% of children with encopresis have a history of constipation or painful defecation. In many patients, the history of constipation or painful defecation is remote, occurring years before the child presents with encopresis. On average, children who have encopresis are symptomatic 5 years before the problem is brought to medical attention.
PhysicalPhysical findings, other than those obtained from the abdominal and rectal examinations, are usually normal.
CausesIn most cases, encopresis is thought to develop as a consequence of chronic constipation with resulting overflow incontinence. Approximately 80-95% of children with encopresis have a history of constipation or painful bowel movements.
DIFFERENTIALSConstipation
|
| Drug Name | Polyethylene glycol powder (MiraLax, GlycoLax) |
|---|---|
| Description | PEG is a long chain of ethylene glycol molecules. The resulting molecule is extremely large, is very poorly absorbed, and functions as an osmotic laxative. These powders are tasteless and odorless and completely dissolve in nearly all liquids including water. These agents can also be used as purgatives in preparation for colonoscopy. At very large dosages, PEG is occasionally difficult to take, and its usage may be associated with nausea, bloating, abdominal cramps, and vomiting. |
| Adult Dose | 17 g mixed in 180-240 mL of fluid PO qd prn |
| Pediatric Dose | Mix one packet (17 g) in 240 mL to yield approximately 1 g per 14 mL; may store refrigerated for 48 h Disimpaction: 1-3 g/kg/d PO divided in 2-4 doses Maintenance therapy in children 6 months to 15 years: Approximately 0.5 g/kg/d PO qd or divided bid |
| Contraindications | Documented hypersensitivity; colitis, ileus, megacolon, bowel perforation, gastric retention, GI obstruction |
| Interactions | Do not administer PO medications within 1 hour of initiation of therapy due to potential risk of reduced absorption |
| Pregnancy | C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus |
| Precautions | Mixing the product in juice or other flavored fluids may make it more palatable; chilled product is more palatable; caution in ulcerative colitis and hot loop polypectomy |
| Drug Name | Magnesium hydroxide (Philip's Milk of Magnesia, Haley's MO) |
|---|---|
| Description | Magnesium is divalent cation maximally absorbed in distal small intestine. At low concentrations, magnesium appears to be absorbed in saturable carrier-mediated process influenced by vitamin D. At high concentrations, absorption appears to occur largely and inefficiently by diffusion. Increased serum magnesium levels may cause cholecystokinin release, which stimulates GI motility and secretion; may explain why some children have abdominal cramping. Mostly flavorless; thick, chalky texture. Most palatable when mixed with fluid (eg, milk, chocolate milk). |
| Adult Dose | 15-60 mL (400 mg/5 mL PO susp) PO qd/bid |
| Pediatric Dose | 1-3 mL/kg/d (400 mg/5 mL susp) PO qd/bid |
| Contraindications | Documented hypersensitivity; colostomy, ileostomy; renal failure, fecal impaction, appendicitis; intestinal obstruction |
| Interactions | Decreases effects of tetracyclines, digoxin, indomethacin, and iron salts |
| Pregnancy | B - Fetal risk not confirmed in studies in humans but has been shown in some studies in animals |
| Precautions | Infants may be more susceptible to magnesium poisoning than older children and adults; overdosage can lead to hypermagnesemia, hypophosphatemia, and secondary hypocalcemia; caution in renal insufficiency because most of a magnesium load is excreted in urine |
| Drug Name | Lactulose (Constilac, Duphalac, Kristalose) |
|---|---|
| Description | Synthetic nonabsorbable disaccharide. Available as 70% solution. Generally well tolerated and tastes sweet. |
| Adult Dose | 10-60 mL PO qd/bid |
| Pediatric Dose | 1-3 mL/kg/d PO qd/bid; not to exceed adult dose |
| Contraindications | Documented hypersensitivity; patients requiring a galactose diet |
| Interactions | Decreases effects of neomycin, laxatives, and antacids |
| Pregnancy | B - Fetal risk not confirmed in studies in humans but has been shown in some studies in animals |
| Precautions | Use caution in diabetes mellitus; often produces flatulence and occasional abdominal cramping at common dosages; dental hygiene should be particularly maintained, as the teeth-coating sugar is known to promote cavities |
| Drug Name | Sorbitol |
|---|---|
| Description | Hyperosmotic laxative. Cathartic actions in GI tract. This alcohol of glucose is largely nonabsorbable. Available as 70% solution. Generally well tolerated and tastes sweet. |
| Adult Dose | 30-150 mL PO of a 70% solution |
| Pediatric Dose | <2 years: Not recommended 2-11 years: 1-3 mL/kg/d PO qd/bid >11 years: Administer as in adults |
| Contraindications | Documented hypersensitivity; anuria |
| Interactions | Reduces effectiveness of other drugs when administered concomitantly |
| Pregnancy | B - Fetal risk not confirmed in studies in humans but has been shown in some studies in animals |
| Precautions | Caution in severe cardiopulmonary or renal impairment and in patients unable to metabolize sorbitol; often produces flatulence and abdominal cramping |
| Drug Name | Magnesium citrate (Evac-Q-mag) |
|---|---|
| Description | Magnesium is divalent cation maximally absorbed in the distal small intestine. At low concentrations, magnesium appears to be absorbed in saturable carrier-mediated process influenced by vitamin D. At high concentrations, magnesium absorption appears to occur largely and inefficiently by diffusion. Increased serum magnesium levels may cause cholecystokinin release, which stimulates GI motility and secretion; may explain why some children have abdominal cramping. May be chilled to improve palatability. |
| Adult Dose | 150-300 mL/d PO qd |
| Pediatric Dose | <6 years: 1-3 mL/kg/d PO 6-12 years: 100-150 mL/d PO >12 years: Administer as in adults |
| Contraindications | Documented hypersensitivity; colostomy, ileostomy, fecal impaction, intestinal obstruction, diabetes mellitus, renal failure |
| Interactions | Decreases effects of tetracyclines, digoxin, indomethacin, and iron salts |
| Pregnancy | B - Fetal risk not confirmed in studies in humans but has been shown in some studies in animals |
| Precautions | Infants may be more susceptible to magnesium poisoning than older children and adults; overdosage can lead to hypermagnesemia, hypophosphatemia, and secondary hypocalcemia; caution in renal insufficiency because most of a magnesium load is excreted in urine; caution in patients taking digoxin and lithium |
| Drug Name | Sodium phosphate oral solution (Fleet Phospho-Soda) |
|---|---|
| Description | Phosphate is a divalent anion largely absorbed in the proximal small intestine. When administered as an enema, only small amounts are absorbed so the phosphate functions as an osmotic agent. Each 15 mL contains 7.2 g monobasic sodium phosphate monohydrate and 2.7 g dibasic sodium phosphate heptahydrate. |
| Adult Dose | 1 tablespoon mixed with 8 oz water PO qd prn; may increase dose not to exceed 3 tablespoons per day; drink at least 8 oz of extra fluid with each dose |
| Pediatric Dose | <5 years: Not recommended 5-9 years: Up to 1/2 tablespoon PO qd taken with 8 oz of fluid 10-11 years: Up to 1 tablespoon PO qd taken with 8 oz of fluid >12 years: Administer as in adults |
| Contraindications | Do not administer sodium phosphate to patients with renal insufficiency because severe and lethal episodes of hyperphosphatemia may develop with resultant hypocalcemia and tetany; fecal impaction |
| Interactions | Sucralfate or antacids that contain aluminum, calcium, or magnesium may bind phosphate in gut and decrease absorption (separate administration by at least 1 h); phosphate may also bind magnesium and reduce its absorption (separate administration by at least 1 h); anion exchange resins (eg, colestipol) may alter phosphate absorption; caution with other drugs that may lower seizure threshold (eg, antipsychotics); caution when coadministered with other drugs that prolong QT interval (eg, antipsychotics, macrolide antibiotics, class IA or class III antiarrhythmic agents); risk of acute phosphate nephropathy may increase with drugs that alter renal perfusion (eg, diuretics, ACE inhibitors, angiotensin II antagonists, NSAIDs) |
| Pregnancy | C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus |
| Precautions | Caution in CHF, and cirrhosis; electrolyte disturbances (eg, hypernatremia, hypokalemia, hyperphosphatemia, hypocalcemia), dehydration, metabolic acidosis, renal failure, tetany, and death have been attributed to prescribing >45 mL as bowel preparation for colonoscopy, surgery, or barium enema and/or prescribing it for people at medical risk |
These agents retard colonic absorption of fecal water and thus soften stool.
| Drug Name | Mineral oil |
|---|---|
| Description | Nonabsorbable fat that softens stool and decreases water absorption, partly by its metabolism in colon to hydroxy fatty acids. Largely tasteless and has oily consistency. Most palatable if cold or mixed into a fluid (eg, orange juice). In many children given high doses, causes seepage of orange oil into underwear, which can produce perianal pruritus. |
| Adult Dose | 30-60 mL PO qd/bid |
| Pediatric Dose | <1 year: Not recommended >1 year: 1-3 mL/kg/d PO qd or divided bid |
| Contraindications | Documented hypersensitivity; do not administer in patients with increased aspiration risk (aspiration of mineral oil can result in lipoid pneumonia) |
| Interactions | Decreases effect of docusate sodium and may decrease absorption of coumarin, PO contraceptives, and fat-soluble vitamins |
| Pregnancy | C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus |
| Precautions | Prolonged administration may produce a deficiency of fat-soluble vitamins; do not administer with food or meals (may cause aspiration leading to lipid pneumonitis) |
These agents directly act on the intestinal mucosa or nerve plexus. They alter water and electrolyte secretion.
| Drug Name | Sennosides (Senokot, Ex-Lax, Fletcher's Castoria, Aloe Vera) |
|---|---|
| Description | Plant alkaloids that stimulate colonic salt and water secretion and promote colonic motility. Often produce abdominal cramping at high doses. Long-term use in animals not been associated with any evidence of cathartic colon, tachyphylaxis, or secondary hyperaldosteronism. |
| Adult Dose | Sennosides: 2 tab (8.3 mg/tab) PO qd; may increase dose; not to exceed 8 tab/d |
| Pediatric Dose | <2 years: Not recommended 2-5 years: 2.5-5 mL/dose (8.8 mg of sennosides/5 mL) PO qd/bid >5 years: 5-10 mL/dose (8.8 mg of sennosides/5 mL) PO qd/bid |
| Contraindications | Documented hypersensitivity; nausea, vomiting, GI bleeding, appendicitis, CHF, fecal impaction |
| Interactions | Decreases effects of anticoagulants |
| Pregnancy | C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus |
| Precautions | Excessive use may lead to electrolyte imbalance, osteomalacia, steatorrhea, and cathartic colon; long-term use may be associated with melanosis coli, or accumulation of brown pigment in colonic mucosa (although it does not appear to have pathologic significance and resolves within several months of discontinuation) |
| Drug Name | Bisacodyl (Dulcolax) |
|---|---|
| Description | Colorless and odorless compound absorbed poorly. Administered PO or PR. Increases colonic peristalsis and stimulates salt and water secretion. |
| Adult Dose | 5-15 mg PO as single dose 10 mg PR as single dose |
| Pediatric Dose | <2 years: Not recommended >2 years: Suppositories: One-half to whole 10-mg suppository PR as a single dose PO: 5-15 mg PO as a single dose |
| Contraindications | Documented hypersensitivity; abdominal pain, nausea or vomiting, GI obstruction |
| Interactions | Decreases effects of warfarin and antacids |
| Pregnancy | C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus |
| Precautions | Caution in ulceration of colon and during pregnancy or lactation |
Several days of enemas are often used to evacuate or disimpact the colon before the start of a regular laxative regimen. Various enema preparations can be used to evacuate the distal colon. Most enema preparations contain osmotically active agents that are not substantially absorbed in the colon. Common examples include phosphate (eg, Fleet pediatric, adult enemas), saline, or milk and molasses. To the author's knowledge, no studies have been performed to compare the effectiveness of various enema preparations. In all likelihood, the effectiveness of any particular preparation depends more on the volume of the enema than on the composition of the enema solution.
| Drug Name | Sodium phosphate enema (Fleet Enema) |
|---|---|
| Description | Phosphate is divalent anion absorbed largely in proximal small intestine. When administered as enema, only small amounts absorbed; functions as osmotic agent. |
| Adult Dose | 1 adult enema (4.5 oz [135 mL]) PR qd/bid prn |
| Pediatric Dose | <2 years: Not recommended 2-11 years: 6 mL/kg/d PR; may administer up to 135 mL qd/bid in older children >11 years: Administer as in adults Note: 1 pediatric enema = 2.25 oz (67.5 mL) |
| Contraindications | Documented hypersensitivity; hyperphosphatemia, hypocalcemia, hypomagnesemia, hyperkalemia, renal failure, congenital megacolon, bowel obstruction, CHF |
| Interactions | Magnesium and aluminum-containing antacids or sucralfate can bind phosphate |
| Pregnancy | C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus |
| Precautions | Caution in CHF, cirrhosis, and electrolyte disturbance (eg, hypernatremia, hypokalemia, hyperphosphatemia, hypocalcemia); dehydration, metabolic acidosis, renal failure, tetany, and death attributed to prescribing >45 mL as bowel preparation for colonoscopy, surgery, or barium enema study and/or prescribing to patients at medical risk |
In addition to the medical therapy outlined above, various modalities have been proposed for the treatment of chronic encopresis.
Even with aggressive medical and behavioral interventions, as many as 30% of children remain symptomatic.23 Unfortunately, no sufficient evidence has enabled clinicians to reliably predict which children successfully respond to specific treatment protocols.
The few data available suggest that family disorganization correlates with a poor response to all forms of treatment. In contrast, none of the demographic, manometric, behavioral, social, academic, or self-esteem measures are clearly associated with response to therapy. No investigators have systematically examined the child's motivation, the family’s motivation, or the state of change to see if it is predictive of their response to treatment.
For excellent patient education resources, visit eMedicine's Esophagus, Stomach, and Intestine Center. Also, see eMedicine's patient education articles, Encopresis and Constipation in Children.
Unless a physical or psychological contraindication is noted, performing a digital rectal examination on every child with encopresis to exclude any underlying anatomic or neurological abnormality that might account for the encopresis, such as an imperforate anus with perineal fistula, a low or unsuspected meningomyelocele, or ultrashort-section Hirschsprung disease, is important.
Article Last Updated: Mar 24, 2008